Last edition
News about "Daiichi Sankyo"
EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
Daiichi Sankyo | 29/06/2026 | By News Bureau
EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
Daiichi Sankyo | 29/06/2026 | By News Bureau
Leica Biosystems, AstraZeneca and Daiichi Sankyo have expanded their strategic collaboration to develop an AI-enabled immunohistochemistry assay and computational pathology solution for evaluating the TROP2 Normalised Membrane Ratio biomarker in NSCLC, aiming to advance biomarker-driven cancer research and future precision medicine approaches.<br />
Daiichi Sankyo | 01/06/2026 | By News Bureau | 136
US FDA Approves Enhertu for New Early Breast Cancer Indications
Enhertu receives new US approvals for use before and after surgery in HER2-positive breast cancer, supported by positive DESTINY-Breast11 and DESTINY-Breast05 phase 3 trial results.
Daiichi Sankyo | 18/05/2026 | By News Bureau | 117
Daiichi Sankyo Unveils 5-Year Oncology Growth Strategy
Daiichi Sankyo launches a 5-year strategy targeting global oncology leadership, aiming for 2.3 trillion yen in oncology revenue by 2030 through new indications, breakthrough technologies, and expanded commercialisation capabilities.
Daiichi Sankyo | 12/05/2026 | By News Bureau | 172
Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer
Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.
Daiichi Sankyo | 13/04/2026 | By News Bureau | 176
Daiichi Sankyo Partners with Imagene AI for Biomarker Discovery
Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.
Daiichi Sankyo | 11/04/2026 | By News Bureau | 175
PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan
Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.
Daiichi Sankyo | 25/03/2026 | By News Bureau | 277
Leveragen Teams Up with Daiichi Sankyo for Next-Gen Biologics Innovation
Daiichi Sankyo will collaborate with Leveragen to apply its in-vivo antibody discovery platform across selected research programmes, supporting early-stage and pre-clinical development of antibody-based biologics across multiple therapeutic areas.
Daiichi Sankyo | 19/03/2026 | By News Bureau | 122
US Food and Drug Administration grants Priority Review to supplemental application for Enhertu to treat HER2-positive breast cancer patients with residual disease after neoadjuvant therapy, with decision expected in Q3 2026.
Daiichi Sankyo | 10/03/2026 | By News Bureau | 144
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy